Suggestions
Chris Gleason
CEO at NextMed Holdings, LLC CEO at Translational Analytics and Statistics, LLC
Chris Gleason is a board member at Our Mayberry, a company focused on revolutionizing charitable giving and fundraising.1 He is a lawyer, entrepreneur, and community philanthropist with multiple leadership roles in charities helping children.3 Gleason has also been involved in various business ventures and has held executive positions in different companies.
In addition to his role at Our Mayberry, Gleason has served as a board member for the Goldwater Institute since 2013.5 He was also recently appointed as the president and CEO of Moximed, a medical device company, in June 2024.2
Gleason has a background in sales leadership, having previously worked as VP of sales at Relievant and VP of sales of interventional urology at Teleflex.2 He has also been involved in political activities, receiving income from Election Watch, a Wisconsin-based group, in 2024.4
It's worth noting that Gleason has recently entered the political arena, running for the position of Pinellas County Supervisor of Elections in Florida for the 2024 election.46 His campaign has been controversial, as he has made unsubstantiated claims about election fraud and criticized the incumbent, Julie Marcus.4
Highlights
Check this out on LinkedIn Learning! I have made it free for you with the link below. #salesstrategy
In August we will celebrate the 25th Anniversary of breaking our first kidney stone. Dr Jim MacDonald treated our first patient at El Dorado Hospital (since closed) in Tucson. In those early years the market was saturated and dominated by large successful incumbents--who fortunately for us had grown fat and happy. My father, a urologist, taught us the importance of measuring our performance and using information derived from those data to continually improve our processes and outcomes. Since that first case we have continued to aggressively innovate and continue to enjoy ever improving outcomes that far surpass the results of the peer reviewed literature. At year 20 of our journey we actively looked for a partner who understood the importance of using modern data science to assess and improve the value of best in class patient care. We joined with Advanced MedTech in 2017 and have not looked back. As the service arm of AMT’s Integrated Urology Platform, we are able to couple best in class medical devices and consumables with our best in class service to provide very high value services to our patients, providers, facilities and payors. We saw better than 20% growth in 2021, and 2022 is looking to be even stronger. We are committed to an aggressive 3 year plan to grow the scope of our services with a new set of offerings that promise to provide our physicians with the autonomy they need to provide the very best services and value to their patients and insurers. We harness technology, human ingenuity and expertise to continually improve the systems that find, train and monitor the very technologists and support staff, leading to every improving patient out-comes. We are proud to be part the AMT Team.
